{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:16Z","timestamp":1792788136215,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Shire Pharmaceutical Developmet Ltd","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1340-y","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T08:14:38Z","timestamp":1497946478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study"],"prefix":"10.1186","volume":"19","author":[{"given":"Barbara","family":"Vigone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Caronni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Baldassarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Fraquelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Montanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Santaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-6258","authenticated-orcid":false,"given":"Lorenzo","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"1340_CR1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989\u20132003.","journal-title":"N Engl J Med."},{"key":"1340_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MCG.0b013e318042d625","volume":"42","author":"EC Ebert","year":"2008","unstructured":"Ebert EC. Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol. 2008;42:5\u201312.","journal-title":"J Clin Gastroenterol."},{"key":"1340_CR3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1529-0131(199810)41:10<1874::AID-ART21>3.0.CO;2-T","volume":"41","author":"I Marie","year":"1998","unstructured":"Marie I, Levesque H, Ducrott\u00e9 P, Denis P, Benichou J, Hellot MF, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum. 1998;41:1874\u201383.","journal-title":"Arthritis Rheum."},{"key":"1340_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1442-2050.1999.00005.x","volume":"12","author":"MA Henry","year":"1999","unstructured":"Henry MA, Harbermann MC, Rocha OM. Esophageal motor disturbances in progressive systemic sclerosis. Dis Esophagus. 1999;12:51\u20133.","journal-title":"Dis Esophagus."},{"key":"1340_CR5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2982.2009.01350.x","volume":"21","author":"TA McNearney","year":"2009","unstructured":"McNearney TA, Sallam HS, Hunnicutt SE, Doshi D, Wollaston DE, Mayes MD, et al. Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients. Neurogastroenterol Motil. 2009;21:1269\u2013e120.","journal-title":"Neurogastroenterol Motil."},{"key":"1340_CR6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/art.1780370902","volume":"37","author":"RW Sjogren","year":"1994","unstructured":"Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37:1265\u201382.","journal-title":"Arthritis Rheum."},{"key":"1340_CR7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/gut.2008.148296","volume":"58","author":"G Lindberg","year":"2009","unstructured":"Lindberg G, T\u00f6rnblom H, Iwarzon M, Nyberg B, Martin JE, Veress B. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut. 2009;58:1084\u201390.","journal-title":"Gut."},{"key":"1340_CR8","doi-asserted-by":"publisher","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, M\u00fcller-Ladner U; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2016. doi:\n10.1136\/annrheumdis-2016-209909\n\n. [Epub ahead of print] PubMed PMID: 27941129.","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"1340_CR9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2125.1991.tb05593.x","volume":"31","author":"A Kahan","year":"1991","unstructured":"Kahan A, Chaussade S, Gaudric M, Freitag B, Amor B, Menkes CJ, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol. 1991;31:683\u20137.","journal-title":"Br J Clin Pharmacol."},{"key":"1340_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s100670200072","volume":"21","author":"SJ Wang","year":"2002","unstructured":"Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, et al. Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002;21:271\u20134.","journal-title":"Clin Rheumatol."},{"key":"1340_CR11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jama.283.9.1131-JFD00001-2-1","volume":"283","author":"JE Henney","year":"2000","unstructured":"Henney JE. From the Food and Drug Administration. JAMA. 2000;283:1131.","journal-title":"JAMA."},{"key":"1340_CR12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157488610789869166","volume":"5","author":"GA Keller","year":"2010","unstructured":"Keller GA, Di Girolamo G. Prokinetic agents and QT prolongation: a familiar scene with new actors. Curr Drug Saf. 2010;5:73\u20138.","journal-title":"Curr Drug Saf."},{"key":"1340_CR13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","volume":"35","author":"J Tack","year":"2012","unstructured":"Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745\u201367.","journal-title":"Aliment Pharmacol Ther."},{"key":"1340_CR14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(01)01087-1","volume":"423","author":"MR Briejer","year":"2001","unstructured":"Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, Leysen JE, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423:71\u201383.","journal-title":"Eur J Pharmacol."},{"key":"1340_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2982.2001.00280.x","volume":"13","author":"MR Briejer","year":"2001","unstructured":"Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13:465\u201372.","journal-title":"Neurogastroenterol Motil."},{"key":"1340_CR16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","volume":"358","author":"M Camilleri","year":"2008","unstructured":"Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344\u201354.","journal-title":"N Engl J Med."},{"key":"1340_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/nmo.12505","volume":"27","author":"J Tack","year":"2015","unstructured":"Tack J, Camilleri M, Dubois D, Vandeplassche L, Joseph A, Kerstens R. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. Neurogastroenterol Motil. 2015;27:397\u2013405.","journal-title":"Neurogastroenterol Motil."},{"key":"1340_CR18","first-page":"45","volume":"3","author":"G Coremans","year":"2008","unstructured":"Coremans G. Prucalopride: the evidence for its use in the treatment of chronic constipation. Core Evid. 2008;3:45\u201354.","journal-title":"Core Evid."},{"key":"1340_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2125.2011.04088.x","volume":"73","author":"B Mendzelevski","year":"2012","unstructured":"Mendzelevski B, Ausma J, Chanter DO, Robinson P, Kerstens R, Vandeplassche L, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203\u20139.","journal-title":"Br J Clin Pharmacol."},{"key":"1340_CR20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1572-0241.2002.05396.x","volume":"97","author":"GE Boeckxstaens","year":"2002","unstructured":"Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97:194\u20137.","journal-title":"Am J Gastroenterol."},{"key":"1340_CR21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis."},{"key":"1340_CR22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480\u201391.","journal-title":"Gastroenterology."},{"key":"1340_CR23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2036.2008.03626.x","volume":"27","author":"GL McCrea","year":"2008","unstructured":"McCrea GL, Miaskowski C, Stotts NA, Macera L, Hart SA, Varma MG. Review article: self-report measures to evaluate constipation. Aliment Pharmacol Ther. 2008;27:638\u201348.","journal-title":"Aliment Pharmacol Ther."},{"key":"1340_CR24","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Guideline on the evaluation of medicinal products for the treatment of chronic constipation. Available at: \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/09\/WC500193391.pdf\n\n. Accessed 12 June 2017."},{"key":"1340_CR25","first-page":"S55","volume":"33","author":"R Gualtierotti","year":"2015","unstructured":"Gualtierotti R, Ingegnoli F, Two R, Meroni PL, Khanna D, Adorni G, et al. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clin Exp Rheumatol. 2015;33:S55\u201360.","journal-title":"Clin Exp Rheumatol."},{"key":"1340_CR26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2015.115","volume":"110","author":"Y Yiannakou","year":"2015","unstructured":"Yiannakou Y, Piessevaux H, Bouchoucha M, Schiefke I, Filip R, Gabalec L, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110:741\u20138.","journal-title":"Am J Gastroenterol."},{"key":"1340_CR27","first-page":"409","volume":"160","author":"JM Jorge","year":"1994","unstructured":"Jorge JM, Wexner SD, Ehrenpreis ED. The lactulose hydrogen breath test as a measure of orocaecal transit time. Eur J Surg. 1994;160:409\u201316.","journal-title":"Eur J Surg."},{"key":"1340_CR28","first-page":"1","volume":"29","author":"A Gasbarrini","year":"2009","unstructured":"Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29:1\u201349.","journal-title":"Aliment Pharmacol Ther."},{"key":"1340_CR29","first-page":"276","volume":"109","author":"S Wellek","year":"2012","unstructured":"Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109:276\u201381.","journal-title":"Dtsch Arztebl Int."},{"key":"1340_CR30","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3899\/jrheum.110225","volume":"38","author":"D Khanna","year":"2011","unstructured":"Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol. 2011;38:1920\u20134.","journal-title":"J Rheumatol."},{"key":"1340_CR31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/01.bor.0000434668.32150.e5","volume":"25","author":"D Khanna","year":"2013","unstructured":"Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol. 2013;25:700\u20136.","journal-title":"Curr Opin Rheumatol."},{"key":"1340_CR32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ajg.2014.74","volume":"109","author":"A Emmanuel","year":"2014","unstructured":"Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol. 2014;109:887\u201394.","journal-title":"Am J Gastroenterol."},{"key":"1340_CR33","first-page":"1314","volume":"27","author":"A Malpeli","year":"2012","unstructured":"Malpeli A, Gonz\u00e1lez S, Vicentin D, Ap\u00e1s A, Gonz\u00e1lez HF. Randomised, double-blind and placebo-controlled study of the effect of a synbiotic dairy product on orocecal transit time in healthy adult women. Nutr Hosp. 2012;27:1314\u20139.","journal-title":"Nutr Hosp."},{"key":"1340_CR34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/nmo.12359","volume":"26","author":"BF Kessing","year":"2014","unstructured":"Kessing BF, Smout AJ, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014;26:1079\u201386.","journal-title":"Neurogastroenterol Motil."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T08:14:55Z","timestamp":1497946495000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1340-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]},"article-number":"145"}}